Treatment of macrophage-related disorders
The present invention provides a method of treating a macrophage related disease comprising administering to a subject in need thereof an effective amount of an oxidative agent or an immunosuppressive agent. The present invention also provides a method of modulating macrophage accumulation or activation comprising administering to a subject in need thereof an effective amount of an oxidative agent or an immunosuppressive agent. The oxidative agent can be chlorite or a chlorite containing compound.
1. A sodium chlorite compound, wherein said compound is a crystalline solid of greater than 95% purity; wherein said compound has an x-ray powder diffraction pattern with peaks expressed in degrees 2θ at about 21, 30, 32, 34, and 39; and wherein said compound has an x-ray powder diffraction (XRPD) pattern as shown in FIG. 6 .
2. A compound of claim 1 , wherein said compound is a crystalline solid of greater than 99% purity.
3. A compound of claim 1 , wherein said compound is a crystalline solid of greater than 99.9% purity.
4. The compound of claim 1 , wherein said compound is substantially free of chlorate.
5. The compound of claim 1 , wherein said compound is substantially free of sulfate.
6. A pharmaceutical composition comprising:
a) the compound of claim 1 ;
b) a pH adjusting agent; and
c) a pharmaceutically acceptable excipient or carrier;
wherein said composition is a liquid that exhibits 25% less pH drift compared to an identical composition without said pH adjusting agent.
7. The composition of claim 6 , wherein said pH adjusting agent is sodium phosphate dibasic.
8. The composition of claim 6 , wherein said compound is substantially free of chlorate.
9. The composition of claim 6 , wherein said compound is substantially free of sulfate.
10. A solid pharmaceutical composition comprising:
a) the compound of claim 1 ; and
b) a pharmaceutically acceptable excipient or carrier.
11. The composition of claim 10 , wherein said compound is substantially free of chlorate.
12. The composition of claim 10 , wherein said compound is substantially free of sulfate.
13. A method of treating a disease associated with migration of monocytes or activated macrophages, said method comprising administering a therapeutically-effective amount of the compound of claim 1 .
14. The method of claim 13 , wherein said disease is characterized by elevated CD16 expression levels in CD14+cells.
15. The method of claim 13 , wherein said disease is characterized by migration of PBMCs in response to a chemoattractant.
16. A method of treating a disease associated with excess activation of monocytes to activated macrophages, said method comprising administering a therapeutically-effective amount of the compound of claim 1 .
17. The method of claim 16 , wherein said disease is associated with excess CD14CD16 expression.
18. The method of claim 16 , wherein said disease is a neurodegenerative disease selected from the group consisting of amyotrophic lateral sclerosis (ALS), Parkinson's Disease (PD), Alzheimer's Disease (AD), and complications thereof.
19. A method of treating Type II diabetes or related complications comprising administering to a subject in need thereof an effective amount of the compound of claim 1 .